These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 30392150)

  • 1. Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.
    El-Achkar A; Souhami L; Kassouf W
    Curr Urol Rep; 2018 Nov; 19(12):108. PubMed ID: 30392150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?
    Mathieu R; Lucca I; Klatte T; Babjuk M; Shariat SF
    Curr Opin Urol; 2015 Sep; 25(5):476-82. PubMed ID: 26125510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.
    Jiang DM; Chung P; Kulkarni GS; Sridhar SS
    Curr Oncol Rep; 2020 Feb; 22(2):14. PubMed ID: 32008105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder Preservation Therapy: A Review of the Literature and Future Directions.
    Cahn DB; Ristau BT; Ghiraldi EM; Churilla TM; Geynisman DM; Horwitz EM; Uzzo RG; Smaldone MC
    Urology; 2016 Oct; 96():54-61. PubMed ID: 27257135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can bladder preservation therapy come to the center stage?
    Inamoto T; Ibuki N; Komura K; Juri H; Yamamoto K; Yamamoto K; Fujita K; Nonomura N; Narumi Y; Azuma H
    Int J Urol; 2018 Feb; 25(2):134-140. PubMed ID: 29171098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimodal therapy in muscle invasive bladder cancer management.
    Polo-Alonso E; Kuk C; Guruli G; Paul AK; Thalmann G; Kamat A; Solsona E; Thalmann G; Urdaneta AI; Zlotta AR; Mir MC
    Minerva Urol Nefrol; 2020 Dec; 72(6):650-662. PubMed ID: 33263367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimodal therapy for muscle-invasive bladder cancer.
    Mathes J; Rausch S; Todenhöfer T; Stenzl A
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1219-1229. PubMed ID: 30324833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.
    Smith ZL; Christodouleas JP; Keefe SM; Malkowicz SB; Guzzo TJ
    BJU Int; 2013 Jul; 112(1):13-25. PubMed ID: 23356411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is trimodal therapy the current standard for muscle-invasive bladder cancer?
    López Valcárcel M; Barrado Los Arcos M; Ferri Molina M; Cienfuegos Belmonte I; Duque Santana V; Gajate Borau P; Fernández Ibiza J; Álvarez Maestro M; Sargos P; López Campos F; Couñago F
    Actas Urol Esp (Engl Ed); 2024 Jun; 48(5):345-355. PubMed ID: 38575067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Can muscle invasive bladder cancer be treated without cystectomy in the future? : New data on trimodal therapy and bladder preservation after systemic therapy alone].
    Hausmann J; Grunewald CM
    Urologie; 2024 Oct; 63(10):985-993. PubMed ID: 39143395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer.
    McHaffie DR; Kruser TJ; Gaston K; Mahoney J; Graham D; Haake M
    Urol Oncol; 2016 Jun; 34(6):271-8. PubMed ID: 27108225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Organ preservation by chemoradiation for bladder cancer].
    Durdux C; Fabiano E; Méjean A
    Cancer Radiother; 2019 Oct; 23(6-7):732-736. PubMed ID: 31400955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
    Arcangeli G; Strigari L; Arcangeli S
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
    Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
    Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.